within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A03A_DrugsForFunctionalGastrointestinalDisorders.A03AB08_Tridihexethyl;

model Tridihexethyl
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.2,
    Cl = 1.9999999999999998e-05,
    adminDuration = 600,
    adminMass = 10 / 1000000,
    adminCount = 1,
    Vd = 0.12,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0008333333333333334,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Tridihexethyl</td></tr><tr><td>ATC code:</td><td>A03AB08</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>10</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>120</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1200</td><td>mL/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Tridihexethyl is an anticholinergic agent formerly used as an antispasmodic and for treating symptoms of peptic ulcer disease and gastrointestinal disorders. It works by inhibiting the action of acetylcholine on muscarinic receptors, thereby reducing smooth muscle spasms in the gastrointestinal tract. Due to safety concerns and the availability of safer alternatives, tridihexethyl is rarely used or approved today.</p><h4>Pharmacokinetics</h4><p>No published human pharmacokinetic models or parameterization for tridihexethyl are currently available in the scientific literature.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.A.A03AB08 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Tridihexethyl;
